Concordance of CSF biomarkers with amyloid PET at baseline in EMERGE/ENGAGE, phase 3 studies of aducanumab in patients with early Alzheimer’s disease

Recent technical performance improvements with the introduction of fully automated platforms have made cerebrospinal fluid (CSF) biomarkers attractive alternatives to positron emission tomography (PET) for brain amyloid pathology confirmation in the diagnosis of Alzheimer’s disease. Growing the body of evidence demonstrating high agreement between CSF biomarkers and amyloid PET across multiple automated platforms is critical to ensuring widespread access to and adoption of CSF biomarkers. Adding to previous data generated with Lumipulse® CSF immunoassays, this study assessed CSF biomarkers on the Elecsys® platform as valid alternatives to PET for amyloid confirmation by conducting a concordance analysis using data from EMERGE and ENGAGE, including performance evaluation of the Elecsys® Gen2 recommended cutoff.